Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Stopping Empagliflozin Unmasks Heart Failure.

Literature DB >> 35136342

Stopping Empagliflozin Unmasks Heart Failure.

Morolake Amole¹, Julio Leey-Casella^1,2.

Abstract

SGLT2 inhibitors have been shown to have a role in the management of heart failure in patients with type 2 diabetes mellitus, but there is a risk of exacerbation when discontinued.

Entities: Chemical

Year: 2021 PMID： 35136342 PMCID： PMC8820197 DOI： 10.12788/fp.0144

Source DB: PubMed Journal: Fed Pract ISSN： 1078-4497

Keyword Cloud
References

8 in total

1. Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes.

Authors: Milton Packer
Journal: Diabetes Care Date: 2018-01 Impact factor: 19.112

2. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245

3. The association between glucose abnormalities and heart failure in the population-based Reykjavik study.

Authors: Inga S Thrainsdottir; Thor Aspelund; Gudmundur Thorgeirsson; Vilmundur Gudnason; Thordur Hardarson; Klas Malmberg; Gunnar Sigurdsson; Lars Rydén
Journal: Diabetes Care Date: 2005-03 Impact factor: 19.112

4. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.

Authors: Elisabetta Patorno; Ajinkya Pawar; Jessica M Franklin; Mehdi Najafzadeh; Anouk Déruaz-Luyet; Kimberly G Brodovicz; Steven Sambevski; Lily G Bessette; Adrian J Santiago Ortiz; Martin Kulldorff; Sebastian Schneeweiss
Journal: Circulation Date: 2019-04-08 Impact factor: 29.690

Review 5. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications.

Authors: David S H Bell; Edison Goncalves
Journal: Diabetes Obes Metab Date: 2019-03-06 Impact factor: 6.577

Stopping Empagliflozin Unmasks Heart Failure.

1. Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes.

2. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

3. The association between glucose abnormalities and heart failure in the population-based Reykjavik study.

4. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.

Review 5. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications.

Review 6. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Review 7. SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice.

Review 8. Type 2 Diabetes and Heart Failure: Challenges and Solutions.